| Dasatinib and navitoclax act synergistically to target NUP98-NSD1+/FLT3-ITD+ acute myeloid leukemia JL Kivioja, A Thanasopoulou, A Kumar, M Kontro, B Yadav, MM Majumder, ... Leukemia 33 (6), 1360-1372, 2019 | 55 | 2019 |
| Interleukin 8 promoter polymorphism predicts the initial response to bevacizumab treatment for exudative age-related macular degeneration A Hautamäki, J Kivioja, S Vavuli, S Kakko, ER Savolainen, MJ Savolainen, ... Retina 33 (9), 1815-1827, 2013 | 38 | 2013 |
| The genetic variant rs4073 A→T of the Interleukin‐8 promoter region is associated with the earlier onset of exudative age‐related macular degeneration A Hautamäki, S Seitsonen, JM Holopainen, JA Moilanen, J Kivioja, ... Acta ophthalmologica 93 (8), 726-733, 2015 | 27 | 2015 |
| The IL-8, VEGF, and CFH polymorphisms and bevacizumab in age-related macular degeneration A Hautamäki, J Kivioja, S Seitsonen, ER Savolainen, MJ Liinamaa, ... Ophthalmology 121 (4), 973-974. e2, 2014 | 19 | 2014 |
| Chimeric NUP98–NSD1 transcripts from the cryptic t(5;11)(q35.2;p15.4) in adult de novo acute myeloid leukemia JL Kivioja, JM Lopez Martí, A Kumar, M Kontro, H Edgren, A Parsons, ... Leukemia & lymphoma 59 (3), 725-732, 2018 | 9 | 2018 |
| FLT3-ITD allelic ratio and HLF expression predict FLT3 inhibitor efficacy in adult AML J Kivioja, D Malani, A Kumar, M Kontro, A Parsons, O Kallioniemi, ... Scientific Reports 11 (1), 23565, 2021 | 7 | 2021 |
| Inferring tumor-specific cancer dependencies through integrating ex vivo drug response assays and drug-protein profiling A Batzilla, J Lu, J Kivioja, K Putzker, J Lewis, T Zenz, W Huber PLoS Computational Biology 18 (8), e1010438, 2022 | 2 | 2022 |
| Dasatinib and navitoclax act synergistically to target NUP98-NSD1 JL Kivioja, A Thanasopoulou, A Kumar, M Kontro, B Yadav, MM Majumder, ... FLT3-ITD+ acute, 2018 | 1 | 2018 |
| Identification of Novel Therapeutic Strategies for NUP98-NSD1-Positive AML By Drug Sensitivity Profiling J Kivioja, M Kontro, A Thanasopoulou, MM Majumder, B Yadav, ... Blood 124 (21), 2160, 2014 | 1 | 2014 |
| Dissecting the Single Cell Landscape of Leukemic Mantle Cell Lymphoma T Wertheimer, H Baniadam, S Reisenauer, M Pohly, L Rindlisbacher, ... Blood 142, 180, 2023 | | 2023 |
| Interleukin-8 production by cells in peripheral blood is associated with age-related macular degeneration lesion activity during anti-VEGF treatment and with variants of the … IJ Immonen, A Robciuc, J Kivioja, J Moilanen, S Seitsonen, I Järvelä, ... Investigative Ophthalmology & Visual Science 60 (9), 115-115, 2019 | | 2019 |
| The NUP98-NSD1 fusion gene in acute myeloid leukemia J Kivioja Helsingin yliopisto, 2019 | | 2019 |
| Discovery of targeted therapies for acute myeloid leukemia patients with NUP98-NSD1 and FLT3-ITD J Kivioja, A Thanasopoulou, M Kontro, A Kumar, B Yadav, MM Majumder, ... Cancer Research 78 (13_Supplement), 1892-1892, 2018 | | 2018 |
| Development of Novel Highly Specific FLT3 Targeted Inhibitors for Combination or Sequential Therapy of Acute Myeloid Leukemia M Sabir, M Hellesoy, J Kivioja, C Engen, C Amiable, M Popa, R Guillon, ... Blood 130, 3349, 2017 | | 2017 |
| Identification of Optimized Compound Combinations for the Treatment of NUP98-NSD1+ AML J Kivioja, A Thanasopoulou, M Kontro, B Yadav, MM Majumder, ... Blood 128 (22), 4711, 2016 | | 2016 |
| Identification of Novel NUP98-NSD1 Fusion Transcripts in Adult DE NOVO Acute Myeloid Leukemia Patients with t (5; 11)(q35; p15. 4) J Kivioja, JL Marti, M Kontro, A Kumar, H Edgren, A Parsons, ... ANNALS OF HEMATOLOGY 94, S78-S78, 2015 | | 2015 |
| Interleukin‐8 promoter polymorphism is associated with the initial repose to bevacizumab in AMD treatment I Immonen, A HAUTAMÄKI, J Kivioja, S Vavuli, S Kakko, ER Savolainen, ... Acta Ophthalmologica 91, 2013 | | 2013 |
| The effects of interleukin‐8, VEGF and CFH polymorphisms on the long‐term response to bevacizumab therapy in exudative age‐related macular degeneration A HAUTAMäKI, J Kivioja, S Vavuli, S Kakko, ER Savolainen, ... Acta Ophthalmologica 91, 2013 | | 2013 |
